Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Sruamsiri, Rosarin ^a   Chaiyakunapruk, Nathorn ^a,b,c,d   Pakakasama, Samart ^e   Sirireung, Somtawin ^e   Sripaiboonkij, Nintita ^e   Bunworasate, Udomsak ^f   Hongeng, Suradej ^e  

^a NARESUAN UNIVERSITY   (Thailand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d MONASH UNIVERSITY MALAYSIA   (Malaysia)

^e MAHIDOL UNIVERSITY   (Thailand)

^f CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Adolescence; Adult; Cost utility analysis; Reduced intensity transplantation; Thalassemia

Indexed keywords

IRON CHELATING AGENT;

ADOLESCENT; ARTICLE; BLOOD TRANSFUSION; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; METHODOLOGY; PROBABILITY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; THAILAND; THALASSEMIA;

ADOLESCENT; BLOOD TRANSFUSION; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON CHELATING AGENTS; MALE; MARKOV CHAINS; MODELS, ECONOMIC; SEVERITY OF ILLNESS INDEX; THAILAND; THALASSEMIA;

MLCS; MLOWN;

EID: 84873245612     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-45     Document Type: Article

References (39)

1. The problem of thalassemia in Thailand. Panich V, Pornpatkul M, Sriroongrueng W, Southeast Asian J Trop Med Public Health 1992 23 Suppl 2 1 8 1364854
2. Advances in allogeneic transplantation for Thalassemia. Lucarelli G, Gaziev J, Blood Rev 2008 22 53 65 10.1016/j.blre.2007.10.001 18039551
3. Outcome of transplantation with unrelated donor bone marrow in children with severe thalassemia. Hongeng S, Pakakasama S, Chaisiripoomkere W, Chuansumrit A, Sirachainan N, Ungkanont A, Jootar S, Bone Marrow Transplant 2004 33 4 377 379 10.1038/sj.bmt.1704361 14676781
4. Outcomes of transplantation with related- and unrelated-donor stem cell in children with severe thalassemia. Hongeng S, Pakakasama S, Chaisiripoomkere W, Chuansumrit A, Sirachainan N, Ungkanont A, Jootar S, Biol Blood Marrow Transplant 2006 12 683 687 10.1016/j.bbmt.2006.02.008 16737942
5. Bone Marrow Transplantation. Armitage J, N Eng J Med 1994 330 12 827 838 10.1056/NEJM199403243301206
6. The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic tranplantation. Bertaina A, Bernardo ME, Mastronuzzi A, Nasa GL, Locatelli F, Ann NY Acad Sci 2010 1202 141 148 10.1111/j.1749-6632.2010.05590.x 20712785
7. Bone marrow transplantation in adult with thalassemia: treatment and long-term follow up. Gaziev J, Sodani P, Polchi P, Andreani M, Lucarelli G, Ann NY Acas Sci 2005 1054 196 205 10.1196/annals.1345.024
8. Reduced intensity stem cell transplantation fir treatment of class 3 Lucarelli severe thalassemia patient. Hongeng S, Pakakasama S, Chuansumrit A, Am J Hematol 2007 82 1095 1103 10.1002/ajh.21002 17674372
9. Thai Health Technology Accessment guideline. Thai Working Group on health Technology Assessment Guidelines in Thailand, J Med Assoc Thai 2008 91 2 1 S88 19255988
10. Health Information Group. Bureau of Health Policy and Strategy, Ministry of Public Health, Thailand: Number of ages-sex specific death rate per 1,000 population http://bps.ops.moph.go.th/Healthinformation/statistic53/statistic53. pdf
11. Survival and complications in thalassemia. Borgna-Pignatti C, Capellini MD, De Stefano P, Ann N Y Sci 2005 1054 40 47 10.1196/annals.1345.006
12. Cost Effectiveness od Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent: US Healthcare Perspective. Delea T, Sofrygin O, Thomas S, Baladi J, Phatak P, Coates T, Pharmaco Economics 2007 25 4 329 342 10.2165/00019053-200725040-00005
13. Results of Long-Term Iron-Chelating Therapy. Gabutti V, Piga A, Acta Heamatologica 1996 95 26 38 10.1159/000203853
14. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. Chouliaras G, Yiannoutsos T, Berdoukas V, Eur J Haematol 2009 82 381 7 10.1111/j.1600-0609.2009.01218.x 19141117
15. Bureau of Trade and Economic indices Ministry of Commerce Thailand, Report for Customer Price Index of Thailand Year 2002-2011 http://www.indexpr. moc.go.th/price-present/TableIndexG-region.asp?nyear=2555&Province-code= 5&table-name=cpig-index-country&type-code=g&check-f=i&comm-code= 4&Submit=+%B5%A1%C5%A7+
16. Drummond MF, Mark JS, George WT, Methods for the economic evaluation of health care programmes: Oxford University Press 2005
17. The MOS 36-item Short Form Health Survey (SF-36): I. Conceptual frame work and item selection. Ware JE, Sherbourne CD, Med Care 1992 30 473 483 10.1097/00005650-199206000-00002 1593914
18. World Bank, Report of GDP per capita http://data.worldbank.org/indicator/ NY.GDP.PCAP.CD
19. Outcome of transplantation with unrelated donor bone marrow in children with severe thalassemia. Hongeng S, Pakakasama S, Chaisiripoomkere W, Transplant 2004 33 377 379
20. Full chimerism in nonmyeloablative stem cell transplantation in a β-thalassemia major patient (class 3 Lucarelli). Hongeng S, Chuansumrit A, Hathirat P, Rerkamnuaychoke B, Chaisiripoomkere W, Jootar S, Bone Marrow Transplant 2002 30 299 314
21. Nonmyeloablative stem cell transplantation with haploidentical donor in a class 3 Lucarelli severe thalassemia patient. Hongeng S, Pakakasama S, Chaisiripoomkere W, Ungkanont A, Jootar S, Bone Marrow Transplant 2004 34 271 272 10.1038/sj.bmt.1704572 15170161
22. Efficacy of a short course (four doses) of methotrexate following bone marrow transplantation for prevention of graft-versus-host disease. Smith BR, Parkman R, Lipton J, Nathan DG, Rappeport JM, Transplantation 1985 39 326 329 10.1097/00007890-198503000-00028 3883600
23. Cytomegalovirus in hematopoietic stem cell transplant recipients (current status, known challenges, and future strategies). Oeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J, Biol Blood MarrowTransplant 2003 9 543 558 10.1016/S1083-8791(03)00287-8
24. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation Blood. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ, 2002 99 4364 4369
25. Briggs A, Sculpher M, Claxton K, Decision modelling for health economic evaluation Oxford, editor: Oxford University Press 2006
26. Bank of Thailand, Report for exchage rate in Thailand http://www2.bot.or.th/statistics/ReportPage.aspx?reportID=123&language=th
27. MOPH Network of Unit Cost, Unit Cost Manual for Hospital: MUCC 2011
28. Economic burden of beta-thalassemai/Hb E and beta-thalassemia major in Thai children. Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol B-o, BMC Res Notes 2010 3 29 37 10.1186/1756-0500-3-29 20181056
29. A cost-utility and budget impact analysis of allogenic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. Leelahavarong P, Chaukledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y, BMC Health Serv Res 2010 10 209 222 10.1186/1472-6963-10-209 20633303
30. Tongsiri S, The Thai population-based preference scores for EQ5D health states Bangkok: Ministry of Public Health 2009 150
31. Properties Testing of the Retranslated SF-36 (Thai Version). Leurmarnkul W, Meetam P, Thai J Pharm Sci 2005 29 1-2 69 90
32. The estimation of a preference-based measure of health from the SF-36. Brazier J, Roberts J, Deverill M, J Health Econ 2002 21 271 294 10.1016/S0167-6296(01)00130-8 11939242
33. Quality of Life Related to Oral versus Subcutaneous Iron Chelation: A Time Trade-off Study. Osborne R, De Abreu LR, Dalton A, Houltram J, Dowton D, Joshua D, Lindeman R, Ho P, Value Health 2007 10 6 451 458 10.1111/j.1524-4733. 2007.00200.x 17970927
34. The Beaver Dam Poster presented at the American Society of Health Outcomes Study: initial catalog of health-state quality factors. Fryback DG, Dasbach EJ, Klein R, Med Decis Making 1993 13 2 89 102 10.1177/ 0272989X9301300202 8483408
35. Making choices in health: WHO guide to cost-effectiveness analysis Geneva: World Health Organization (WHO), Tan-Torres Edejer T, Baltussen R, Adam T, 2003
36. The threshold at which an intervention becomes cost-effective Meeting of the Subcommittee for Development of the National List of Essential Medicine 9/2007, Food and Drug Administration Ministry of Public Health Thailand (20 Dec, 2007)
37. The Commission on Macroeconomics and Health, c Geneva: World Health Organization (WHO) Macroeconomics and Health. 2002
38. Handling uncertainty of the economic evaluation result: sensitivity analysis. Limwattananon S, J Med Assoc Thai 2008 91 suppl 2 59 S65 19253488
39. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E, Baronciani D, Andreani M, Manna M, Nesci S, Blood 2004 104 4 1201 1203 10.1182/blood-2003-08-2800 15039283